Navigation Links
Origin BioMed Awarded Red Herring Top 100 Global Company
Date:1/27/2009

Halifax-based consumer health products company recognized as a world technology leader

HALIFAX, Nova Scotia, Jan. 27 /PRNewswire/ -- Origin BioMed Inc., a privately-held Canadian consumer health products company, today announced that it has been awarded as one of the Red Herring Top 100 Global Companies.

Red Herring Top 100 Global Companies are chosen from winners and finalists of the previous competitions for North America, Europe and Asia Red Herring Top 100 Companies. Out of 1,800 successful and highly eligible companies, the Red Herring editorial team deployed a detailed process to drill-down the best companies first to 200 finalists, then to the top 100 winners of this global award. Evaluations were made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration.

The announcement of the winners was made at the Red Herring 100 Global taking place in San Diego from January 14-16, 2009. Present among the finalists were elite executives and venture capital leaders from around the world.

"We were so pleased to announce Origin BioMed Inc. as a Red Herring Top 100 Global Company," commented Red Herring publisher Alex Vieux. "Origin BioMed has proven to be a company excelling in their industry and its ripples have turned into waves. It was difficult for us to narrow down, but we are pleased to have included Origin BioMed in our list of promising companies. We look forward to the changes it makes to the non-prescription drug industry in the future." Origin was one of only 4 Canadian companies to receive the Award, with companies from 25 other countries also receiving the award.

"Since its inception, Origin's mission has been to leverage cutting edge technology to bring scientifically proven natural products to professional care givers and consumers. We strive to increase over-the-counter treatment options for nerve pain, and Red Herring's recognition demonstrates that our model has begun to position us as a global leader in our field," said Robert Cervelli, President and CEO, Origin BioMed. "It was a real honour to accept this award on behalf of the entire dynamic team at Origin," he added.

Origin BioMed's leading drug product, Neuragen(R), is the first non-prescription topical treatment for rapid relief of diabetic and post-shingles nerve pain. Neuragen(R) is available in all leading pharmacies in Canada and the United States.

About Origin BioMed Inc.

Origin BioMed, Inc. is a privately-held Canadian consumer health products company with business operations throughout the U.S. and Canada. Headquartered in Halifax, Nova Scotia, Origin BioMed Inc. manufactures health products with the highest quality active ingredients, at therapeutic levels, with evidence of scientific or clinical efficacy since 2001. Its leading drug product, Neuragen(R), helps relieve pain caused by diabetic nerve damage. For more information, please visit: www.originbiomed.com or www.neuragen.com.

    Contact:
    Robert Silverstein
    VP Operations
    902-444-8696
    silverstein@originbiomed.com

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available on the Internet at www.redherring.com.

    Anam Alpenia
    Red Herring, Inc.
    Phone: 650-428-2900
    Email: aalpenia@redherring.com


'/>"/>
SOURCE Origin BioMed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
2. Covance Decides to Pursue Its Original Preclinical Strategy in China
3. Brewing better beer: Scientists determine the genomic origins of lager yeasts
4. San Diegos Original Biotech Company Celebrates 30th Anniversary With Reunion
5. Experts prove the geochemical origin of part of the CO2 emissions in semiarid climates
6. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
7. Three Expert Opinion Journals now Publishing Original Research
8. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
10. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
11. Bavarian Nordics Case Against Oxford BioMedica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular ... CE Mark its Chlamydia trachomatis (CT) test to be launched ... the IVD Directive (98/79/EC), the CT test is now cleared ... --> The launch of the io® CT ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, ... Excellence in Education Sponsors Teacher Training Program , Bite of Science Dinner Event ... Center for Excellence in Education (CEE) will sponsor a Bite of Science professional ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical industry ... a host of launch activities including the identification and ... launch activity is especially high in the oncology therapeutic ... Best Practices and the Role of Medical Affairs in ... focused on oncology therapies find better ways to utilize ...
(Date:2/5/2016)... February 5, 2016 Amarantus BioScience ... company focused on developing products for Regenerative Medicine, Neurology ... Pediatric Disease Designation (RPDD) from the US Food and ... MANF. MANF was previously granted orphan drug designation (ODD) ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
Breaking Biology News(10 mins):